FTC Drops Reverse-Payment Claim Against AbbVie Ending Antitrust Lawsuit
- August 06, 2021
The Federal Trade Commission (FTC) is withdrawing its remaining reverse-payment claim against AbbVie Inc. in the long-running antitrust lawsuit involving the testosterone drug AndroGel.
ARTICLE TAGS
You must be logged in to access this content.